EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W Pipe iD, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri iD, Víctor Jiménez-Yuste iD, Flora Peyvandi iD, Guy Young iD, Johannes Oldenburg iD, Maria Elisa Mancuso iD, Kaan Kavakli und 6 weitere

Blood · 04.04.2024 · 143 (14) · 1355-1364

DOI: 10.1182/blood.2023021832 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Blood, erschienen am 04.04.2024. Verfasst von Steven W Pipe und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Thrombotic Microangiopathies, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated to infants, designed to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in those aged ≤12 months with severe HA without factor VIII (FVIII) inhibitors. Participants in this phase 3b trial received emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks and are continuing emicizumab during the 7-year long-term follow-up. Efficacy end points included annualized bleed rate (ABR): treated, all, treated spontaneous, and treated joint bleeds. Safety end points included adverse events (AEs), thromboembolic events (TEs), thrombotic microangiopathies (TMAs), and immunogenicity (anti-emicizumab antibodies [ADAs] and FVIII inhibitors). At primary analysis, 55 male participants had received emicizumab (median treatment duration: 100.3; range, 52-118 weeks). Median age at informed consent was 4.0 months (range, 9 days to 11 months 30 days). Model-based ABR for treated bleeds was 0.4 (95% confidence interval, 0.30–0.63), with 54.5% of participants (n = 30) having zero treated bleeds. No ICH occurred. All 42 treated bleeds in 25 participants (45.5%) were traumatic. Nine participants (16.4%) had ≥1 emicizumab-related AE (all grade 1 injection-site reactions). No AE led to treatment changes. No deaths, TEs, or TMAs occurred. No participant tested positive for ADAs. Two participants were confirmed positive for FVIII inhibitors. This primary analysis of HAVEN 7 indicates that emicizumab is efficacious and well tolerated in infants with severe HA without FVIII inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificThrombotic MicroangiopathiesAntibodies, Monoclonal, HumanizedInfantHumansMaleInfant, NewbornFactor VIIIHemorrhageIntracranial Hemorrhages

Substanzen

Factor VIIIemicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of Michigan, Ann Arbor, MI.
  • School of Medicine, Cardiff University, Cardiff, United Kingdom.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Sheba Medical Center, Ramat Gan, Israel.
  • Tel Aviv University, Tel Aviv, Israel.
  • La Paz University Hospital-IdiPaz, Autónoma University, Madrid, Spain.

ORCID-Profile: Steven W Pipe, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Karin Fijnvandraat

Zitieren

APA

Pipe, S. W., Collins, P., Dhalluin, C., Kenet, G., Schmitt, C., Buri, M., Jiménez-Yuste, V., Peyvandi, F., Young, G., Oldenburg, J., Mancuso, M. E., Kavakli, K., Kiialainen, A., Deb, S., Niggli, M., Chang, T., Lehle, M., & Fijnvandraat, K. (2024). Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood, 143(14), 1355-1364. https://doi.org/10.1182/blood.2023021832

Vancouver

Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143(14):1355-1364. doi:10.1182/blood.2023021832

BibTeX
@article{Pipe2024,
  author = {Pipe, Steven W and Collins, Peter and Dhalluin, Christophe and Kenet, Gili and Schmitt, Christophe and Buri, Muriel and Jiménez-Yuste, Víctor and Peyvandi, Flora and Young, Guy and Oldenburg, Johannes and Mancuso, Maria Elisa and Kavakli, Kaan and Kiialainen, Anna and Deb, Sonia and Niggli, Markus and Chang, Tiffany and Lehle, Michaela and Fijnvandraat, Karin},
  title = {Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial},
  journal = {Blood},
  year = {2024},
  volume = {143},
  number = {14},
  pages = {1355--1364},
  doi = {10.1182/blood.2023021832}
}
Kostenlos starten →